| 词条 | Pemtumomab |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 400279517 | image = | type = mab | mab_type = | source = o | target = MUC1 | tradename = Theragyn | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Intraperitoneal | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | chemical_formula = | molecular_weight = }}Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] {{As of|2009}}, it is undergoing Phase III clinical trials.[2] It has been granted orphan drug status in Europe.[3] References1. ^{{cite journal|pmid=18661524|year=2008|last1=Oei|first1=AL|last2=Moreno|last3=Verheijen|last4=Sweep|last5=Thomas|last6=Massuger|last7=Von Mensdorff-Pouilly|title=Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer|volume=123|issue=8|pages=1848–53|doi=10.1002/ijc.23725|journal=International Journal of Cancer|first2=M|first3=RH|first4=FC|first5=CM|first6=LF|first7=S}} {{Monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^ClinicalTrials.gov 3. ^Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status{{dead link|date=February 2019|bot=medic}}{{cbignore|bot=medic}} 3 : Monoclonal antibodies for tumors|Orphan drugs|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。